Shionogi gets partial change approval for intramuscular COVID vaccine
Shionogi & Co., Ltd. says its Covgoze for intramuscular injection (JN.1-adapted), recombinant protein COVID-19 vaccine, received partial change approval in Japan.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.